Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TN 201

Next Previous
X
Search
Drug Profile

TN 201

Alternative Names: TN-201

Latest Information Update: 23 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tenaya Therapeutics
  • Class Cardiovascular therapies; Gene therapies
  • Mechanism of Action Gene transference; Myosin-binding protein C replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypertrophic cardiomyopathy
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypertrophic cardiomyopathy

Most Recent Events

  • 17 Dec 2024 Pharmacodynamics, efficacy and adverse events data from a phase I/II trial in Hypertorphic cardiomyopathy released by Tenaya Therapeutics
  • 08 Aug 2024 The US FDA grants the rare pediatric disease designation (RPDD) to TN 201 for the treatment of Hypertrophic Cardiomyopathy (In children, In adolescents, In adults)
  • 31 Dec 2023 Tenaya Therapeutics has patent pending for TN 201 in USA and foreign countries, prior to December 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top